Zacks: Analysts Anticipate Joint Corp (NASDAQ:JYNT) to Announce $0.03 Earnings Per Share

Wall Street analysts forecast that Joint Corp (NASDAQ:JYNT) will announce $0.03 earnings per share for the current quarter, Zacks reports. Three analysts have issued estimates for Joint’s earnings. Joint reported earnings of $0.01 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 200%. The firm is expected to announce its next quarterly earnings report on Thursday, November 14th.

On average, analysts expect that Joint will report full year earnings of $0.20 per share for the current fiscal year, with EPS estimates ranging from $0.19 to $0.21. For the next fiscal year, analysts anticipate that the company will report earnings of $0.39 per share, with EPS estimates ranging from $0.28 to $0.48. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Joint.

Joint (NASDAQ:JYNT) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.03 EPS for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.01. The company had revenue of $11.17 million for the quarter, compared to analyst estimates of $11.08 million. Joint had a net margin of 5.38% and a return on equity of 114.93%.

JYNT has been the topic of several research analyst reports. Zacks Investment Research downgraded shares of Joint from a “buy” rating to a “hold” rating in a research note on Saturday, August 10th. TheStreet downgraded shares of Joint from a “b-” rating to a “c” rating in a research note on Tuesday, September 3rd. Maxim Group restated a “buy” rating and issued a $25.00 price objective on shares of Joint in a research note on Friday, August 9th. B. Riley set a $23.00 price objective on shares of Joint and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Lake Street Capital raised their price objective on shares of Joint from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $23.83.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Royal Bank of Canada boosted its stake in Joint by 23.1% during the second quarter. Royal Bank of Canada now owns 5,541 shares of the company’s stock worth $101,000 after buying an additional 1,041 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Joint by 1,199.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,767 shares of the company’s stock valued at $32,000 after purchasing an additional 1,631 shares in the last quarter. Winslow Evans & Crocker Inc. acquired a new stake in shares of Joint in the 3rd quarter valued at $36,000. Renaissance Technologies LLC boosted its stake in shares of Joint by 2.1% in the 2nd quarter. Renaissance Technologies LLC now owns 108,371 shares of the company’s stock valued at $1,972,000 after purchasing an additional 2,200 shares in the last quarter. Finally, Marshall Wace North America L.P. acquired a new stake in shares of Joint in the 1st quarter valued at $47,000. Hedge funds and other institutional investors own 62.76% of the company’s stock.

Shares of Joint stock traded down $0.30 during midday trading on Wednesday, hitting $17.61. The company had a trading volume of 1,681 shares, compared to its average volume of 132,596. The business’s 50 day simple moving average is $17.97 and its two-hundred day simple moving average is $17.74. The stock has a market cap of $249.81 million, a PE ratio of 443.50 and a beta of 1.02. The company has a debt-to-equity ratio of 3.33, a current ratio of 1.04 and a quick ratio of 1.04. Joint has a 1-year low of $6.51 and a 1-year high of $21.80.

About Joint

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States.

Featured Article: What is Put Option Volume?

Get a free copy of the Zacks research report on Joint (JYNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.